EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

16 Sep 2016

• By Aine Slowey

New data from Novo Nordisk supporting its GLP-1 agonist will fortify the firm's new drug applications, strengthen its position in price negotiations and boost its chances of reimbursement.

Pipeline — Good news for Novo's diabetes pipeline

EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

More from Alimentary/Metabolic

More from Therapy Areas